The Australia-based CRO announced the accords at the recent KoNECT 2024 conference, describing them as an “important milestone in the company’s strategic expansion across the Asia-Pacific region.”
The three sites are: the CHA University Bundang Medical Center, a 1,000-bed hospital with a focus on research; the Korea University Medicine centre in Seoul; and the Dong-A University Hospital, Clinical Trial Center in Busan.
Avance CEO Yvonne Lungershausen framed the deals as part of the CROs ongoing expansion effort.
“As Avance Clinical continues to grow its global footprint, these partnerships with respected institutions will further enhance our ability to offer flexible, efficient, and high-quality clinical trial services in the Asia-Pacific region.”
